Executive editor Kevin Depew offers his take on the Apple (AAPL) iPhone -- hell yes, he'd buy one -- and notes that the big story is the price cut on top of additional features.



Kevin takes a hard look at the biotech sector and specifically the iShares Nasdaq Biotech Index ETF (IBB). The normal seasonal run for biotech typically begins in August, but we're seeing some demand creep in a smidge earlier this year.



On days like this it's important to look at relative strength - those sectors and stocks outperforming the market, even if that outperformance is simply a case of not dipping as much as the market. Those are the areas that rebound first.